Drug Approval

Name: Elucirem

Active Ingredient: gadopiclenol

Indications: To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body

Approval Date: 9/21/2022

Company: Guerbet LLC

Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *